Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2

Cell Proliferation

Volumn 44, Issue 4, 2011, Pages 380-390

  Pepper, C ^a   Mahdi, J G ^b   Buggins, A G S ^c   Hewamana, S ^d   Walsby, E ^a   Mahdi, E ^a   Al Haza'a, A ^b   Mahdi, A J ^a   Lin, T T ^a   Pearce, L ^a   Morgan, L ^a   Bowen, I D ^e   Brennan, P ^a   Fegan, C ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY BENZOATE ZINC; 4 HYDROXY BENZOATE ZINC; ACETYLSALICYLIC ACID DERIVATIVE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CD40 LIGAND; CYCLOOXYGENASE 2; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE;

AGED; ANIMALS; ANTIGENS, CD38; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; CASPASE 3; CASPASE 9; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MICE; OLIGOPEPTIDES; PARABENS; SALICYLIC ACID; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 79959749306     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2011.00760.x     Document Type: Article

References (50)

1. Bannerji R, Byrd JC (2000) Update on the biology of chronic lymphocytic leukemia. Curr. Opin. Oncol. 12, 22-29.
2. Byrd JC, Stilgenbauer S, Flinn IW (2004) Chronic lymphocytic leukemia. Hematology, Am. Soc. Hematol. Ed. Program, 163-183.
3. Keating MJ (1999) Chronic lymphocytic leukemia. Semin. Oncol. 26, 107-114.
4. Kolb JP, Kern C, Quiney C, Roman V, Billard C (2003) Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3, 261-286.
5. Pepper C, Bentley P, Hoy T (1996) Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukemia. Br. J. Haematol. 95, 513-517.
6. Sanz L, Garcia-Marco JA, Casanova B, de La Fuente MT, García-Gila M, Garcia-Pardo A, et al. (2004) Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochem. Biophys. Res. Commun. 315, 562-567.
7. Buggins AGS, Pepper CJ (2010) The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk. Res. 34, 837-842.
8. Kay NE (2006) Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia. Semin. Hematol. 43, S50-S54.
9. Lam CC, Ma ES, Kwong YL (2005) Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia. Am. J. Hematol. 79, 288-290.
10. Lamanna N, Weiss MA (2006) Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia. Semin. Hematol. 43, S44-S49.
11. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112, 975-980.
12. Robak T (2005) Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies. Drugs Aging 22, 983-1012.
13. Yee KW, O'Brien SM (2006) Emerging drugs for chronic lymphocytic leukaemia. Expert Opin. Emerg. Drugs 11, 167-189.
14. Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D et al. (1998) Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 92, 1406-1414.
15. Hall JG, Cory AH, Hickerson DH, Cory JG (2001) Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells. Anticancer Res. 21, 173-180.
16. Nagaoka T, Banskota AH, Tezuka Y, Midorikawa K, Matsushige K, Kadota S (2003) Caffeic acid phenethyl ester (CAPE) analogues: potent nitric oxide inhibitors from the Netherlands propolis. Biol. Pharm. Bull. 26, 487-491.
17. Kellner C, Zunino SJ (2004) Nitric oxide is synthesized in acute leukemia cells after exposure to phenolic antioxidants and initially protects against mitochondrial membrane depolarization. Cancer Lett. 215, 43-52.
18. Cory AH, Cory JG (2005) Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells. In Vivo 19, 31-35.
19. Mahdi JG, Alkarrawi MA, Mahdi AJ, Humam D, Bowen ID (2006) Calcium salicylate mediated apoptosis in human HT-1080 fibrosarcoma cells. Cell Prolif. 39, 249-260.
20. Kasum CM, Blair CK, Folsom AR, Ross JA (2003) Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol. Biomarkers Prev. 12, 534-537.
21. Riboli E, Norat T (2003) Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am. J. Clin. Nutr. 78, 559S-569S.
22. Meyers KJ, Watkins CB, Pritts MP, Liu RH (2003) Antioxidant and antiproliferative activities of strawberries. J. Agric. Food Chem. 51, 6887-6892.
23. Weiss JR, Baker JA, Baer MR, Menezes RJ, Nowell S, Moysich KB (2006) Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. Leuk. Res. 30, 164-169.
24. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S et al. (2005) Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1beta-induced neovascularization and tumor growth. J. Clin. Invest. 115, 2979-2991.
25. Zhi YH, Liu RS, Song MM, Tian Y, Long J, Tu W et al. (2005) Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J. Gastroenterol. 11, 3724-3728.
26. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW et al. (2004) Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 64, 7439-7446.
27. Park JH, Kang KH, Kim SH, Lee JH, Cho CM, Kweon YO et al. (2005) Expression of cyclooxygenase-2 and Bcl-2 in human gastric adenomas. Korean J. Intern. Med. 20, 198-204.
28. Ryan EP, Pollock SJ, Kaur K, Felgar RE, Bernstein SH, Chiorazzi N et al. (2006) Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukaemia B cells. Clin Immunol. 120, 76-90.
29. Secchiero P, Barbarotto E, Gonelli A, Tiribelli M, Zerbinati C, Celeghini C et al. (2005) Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells. Am. J. Pathol. 167, 1599-1607.
30. D'Acquisto F, May MJ, Ghosh S (2002) Inhibition of nuclear factor kappa B (NF-kB): an emerging theme in anti-inflammatory therapies. Mol. Interv. 2, 22-35.
31. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML et al. (2008) The NF-kB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111, 4681-4689.
32. Lindhagen E, Nissle S, Leoni L, Elliott G, Chao Q, Larsson R et al. (2007) R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother. Pharmacol. 60, 545-553.
33. Lentzsch S, Elliott G, Roodman GD (2007) SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma. Arch. Pharm. (Weinheim) 340, 511-516.
34. Robak P, Linke A, Cebula B, Robak T, Smolewski P (2006) Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leuk. Lymphoma 47, 2625-2634.
35. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206.
36. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. (2008) Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112, 3807-3817.
37. Mahdi JG, Pepper CJ, Alkarrawi MA, Mahdi AJ, Bowen ID (2010) Sub-millimolar concentration of the novel phenolic-based compound, JMC-18, induce apoptosis in human HT-1080 fibrosarcoma cells. Cell Prolif. 43, 95-102.
38. Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY et al. (2007) SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 109, 2130-2138.
39. Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J et al. (2010) Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res. 70, 7523-7533.
40. Appleby S, Ristimäki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclo-oxygenase-2 gene. Biochem. J. 302, 723-727.
41. Iglesias-Serret D, Piqué M, Barragán M, Cosialls AM, Santidrián AF, González-Gironès DM et al. (2010) Aspirin induces apoptosis in human leukaemia cells independently of NF-kB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis 15, 219-229.
42. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL et al. (2007) Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26, 1166-1177.
43. Hewamana S, Lin TT, Rowntree C, Karunanithi K, Pratt G, Hills R et al. (2009) Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J. Clin. Oncol. 27, 763-769.
44. Burger JA, Burger M, Kipps TJ (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658-3667.
45. Jurlander J (1998) The cellular biology of B-cell chronic lymphocytic leukemia. Crit. Rev. Oncol. Hematol. 27, 29-52.
46. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ et al. (2008) CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111, 5173-5181.
47. Caligaris-Cappio F, Ghia P (2008) Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J. Clin. Oncol. 26, 4497-4503.
48. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk. Res. 31, 899-906.
49. Edelmann J, Klein-Hitpass L, Carpinteiro A, Führer A, Sellmann L, Stilgenbauer S et al. (2008) Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk. Res. 32, 1565-1572.
50. Ghia P, Caligaris-Cappio F (2000) The indispensable role of microenvironment in the natural history of low-grade cell neoplasms. Adv. Cancer Res. 79, 157-173.